AACR Presentation Update

Physiomics PLC
08 April 2008





                                                                  Physiomics plc
                                                             The Magdalen Centre
                                                         The Oxford Science Park
                                                          Robert Robinson Avenue
                                                                          Oxford
                                                                         OX4 4GA
                                                                              UK

                                                                Tel [phone]
                                                                Fax [phone]

08 April 2008



                 Physiomics plc ('Physiomics' or 'the Company')

Physiomics to present on Cyclacel Pharmaceuticals collaboration on Aurora Kinase
    research program at the Annual Meeting of American Association of Cancer
                               Research ('AACR')

Physiomics plc (AIM: PYC), the Oxford, UK based  systems biology company, is
pleased to announce that it will be participating in the 2008 AACR Annual
Meeting, taking place in San Diego, on 12-16 April 2008.  Dr Christophe
Chassagnole, Chief Operating Officer of Physiomics, will present the results of
a recent collaboration with Cyclacel pharmaceuticals Inc. (NASDAQ: CYCC, NASDAQ:
CYCCP). It will be shown how Physiomics technologies have been used to support a
pre-clinical research program on a novel Aurora Kinase inhibitor CYC116 that has
since entered in a phase 1 clinical research program. The abstract ('Systems
biology analysis of a novel Aurora kinase inhibitor: CYC116', No 1645) will be
published in the 2008 Proceeding of the AACR and will be presented in the poster
session 'Cellular and Molecular Biology 16', scheduled for 8:00 am 12:00 pm on
14 April.


More information about the conference may be found at www.aacr.org


For further information:
Physiomics plc                                         [phone]
Dr Christophe Chassagnole, COO
E-mail: [e-mail]
Grant Thornton Corporate Finance                       [phone]
Philip Secrett, Colin Aaronson


About Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company
applying simulations of cell behaviour to drug development to reduce the high
attrition rates of clinical trials. As 80-90 per cent of all clinical drug
candidates fail to reach the market, estimates1 show that an overall ten per
cent improvement in success rates could reduce the cost of one drug's
development by as much as $242 million, from the current estimate of around $800
million.

Physiomics develops computational systems biology models to predict and
understand cancer drug efficacy from pre-clinical research to clinical
development. Physiomics has created detailed mathematical models incorporating
most important molecular events taking place during the human cell cycle and
apoptosis processes. Physiomics developed SystemCell(R) technology, a
multi-cellular environment software, which enables the simulation of population
of 'virtual cells'.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in
2004. For further information, please visit www.physiomics-plc.com


SystemCell(R) is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002






                      This information is provided by RNS
            The company news service from the London Stock Exchange